Immunosuppressive Macrolides of the Type FK 506: A Novel Class of Topical Agents for Treatment of Skin Diseases?
- 1 June 1992
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 98 (6), 851-855
- https://doi.org/10.1111/1523-1747.ep12456939
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Efficacy of cyclosporin A in psoriasis: a summary of the United States' experienceBritish Journal of Dermatology, 1990
- Four years of experience with cyclosporin A for psoriasisBritish Journal of Dermatology, 1990
- Cyclosporin A in atopic dermatitisBritish Journal of Dermatology, 1990
- Intralesional cyclosporine in the treatment of psoriasis: A clinical, immunologic, and pharmacokinetic studyJournal of the American Academy of Dermatology, 1990
- (5) Topical cyclosporin A in alopecia totalis: failure of therapeutic effect due to lack of penetrationBritish Journal of Dermatology, 1989
- EFFECT OF A NEW IMMUNOSUPPRESSIVE AGENT, FK506, ON HUMAN LYMPHOCYTE RESPONSES IN VITROTransplantation, 1989
- EFFECT OF A NEW IMMUNOSUPPRESSIVE AGENT, FK506, ON HUMAN LYMPHOCYTE RESPONSES IN VITROTransplantation, 1989
- FK-506 — How much potential?Immunology Today, 1989
- Topical cyclosporins in psoriasisJournal of the American Academy of Dermatology, 1988
- Cyclosporin A inhibits phorbol ester-induced cellular proliferation and tumor promotion as well as phosphorylation of a 100-kd protein in mouse epidermisCarcinogenesis: Integrative Cancer Research, 1987